Rheumatoid Arthritis and Cancer Risk

By Mellemkjaer L.   Linet M.S.   Gridley G.   Frisch M.   Moller H.   Olsen J.H.  

European Journal of Cancer, Vol. 32, Iss. 10, 1996-09 ,pp. : 1753-1757

Elsevier

Access to resources Recommend Favorite

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer

By Kusaba Hitoshi   Esaki Taito   Kishimoto Junji   Uchino Keita   Arita Shuji   Kumagai Hozumi   Mitsugi Kenji   Akashi Koichi   Baba Eishi  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 29-34

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

By Cohen Steven   Gallo James   Lewis Nancy   Alpaugh R.   Gentner Louis   Rogatko André   Yeslow Gwen   Schol Jessie   Verhaeghe Tom   Zannikos Peter   Palmer Peter   Weiner Louis   Meropol Neal  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 513-518

Springer Publishing Company

Access to resources Recommend Favorite

Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer

By Merlin Federica   Prochilo Tiziana   Kildani Basem   Tucci Alessandra   Ferrari Samantha   Rossi Giuseppe   D'adda Paolo   Beretta Giordano Domenico  

Acta Oncologica, Vol. 47, Iss. 3, 2007-09 ,pp. : 464-466

Informa Healthcare

Access to resources Recommend Favorite

Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: Ιmpact on cancer therapy

By              

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 877-886

Spandidos Publications

Access to resources Recommend Favorite